Healthcare provider profile · identity verified

Mary E. Alexander, M.D.

Internal Medicine · LA MESA, CA · NPI 1538177845

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Losartan Potassium	Losartan Potassium	542	155
Atorvastatin Calcium	Atorvastatin Calcium	468	139
Levothyroxine Sodium	Levothyroxine Sodium	326	91
Amlodipine Besylate	Amlodipine Besylate	307	94
Lisinopril	Lisinopril	216	65
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	209	42
Hydrochlorothiazide	Hydrochlorothiazide	155	55
Omeprazole	Omeprazole	134	50
Escitalopram Oxalate	Escitalopram Oxalate	130	38
Gabapentin	Gabapentin	123	38
Zolpidem Tartrate	Zolpidem Tartrate	117	24
Alendronate Sodium	Alendronate Sodium	111	33
Eliquis	Apixaban	104	26
Lorazepam	Lorazepam	101	24
Metoprolol Succinate	Metoprolol Succinate	101	31
Albuterol Sulfate Hfa	Albuterol Sulfate	98	37
Metformin Hcl	Metformin Hcl	98	31
Metoprolol Tartrate	Metoprolol Tartrate	96	31
Simvastatin	Simvastatin	94	30
Atenolol	Atenolol	90	30
Furosemide	Furosemide	90	27
Rosuvastatin Calcium	Rosuvastatin Calcium	90	24
Pantoprazole Sodium	Pantoprazole Sodium	88	27
Metformin Hcl Er	Metformin Hcl	75	27
Celecoxib	Celecoxib	71	37
Estradiol	Estradiol	68	26
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	68	14
Citalopram Hbr	Citalopram Hydrobromide	67	18
Potassium Chloride	Potassium Chloride	67	26
Trazodone Hcl	Trazodone Hcl	67	20
Alprazolam	Alprazolam	66	17
Carvedilol	Carvedilol	66	16
Fluticasone Propionate	Fluticasone Propionate	62	25
Ibuprofen	Ibuprofen	58	15
Tramadol Hcl	Tramadol Hcl	57	19
Ibandronate Sodium	Ibandronate Sodium	53	21
Pravastatin Sodium	Pravastatin Sodium	53	16
Sertraline Hcl	Sertraline Hcl	53	17
Glipizide Er	Glipizide	51	16
Meloxicam	Meloxicam	51	12
Famotidine	Famotidine	50	20
Ozempic	Semaglutide	50	suppressed
Rybelsus	Semaglutide	49	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	46	17
Synthroid	Levothyroxine Sodium	45	14
Acyclovir	Acyclovir	42	18
Mirtazapine	Mirtazapine	42	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	42	suppressed
Warfarin Sodium	Warfarin Sodium	42	suppressed
Lovastatin	Lovastatin	39	11
Triamcinolone Acetonide	Triamcinolone Acetonide	38	24
Allopurinol	Allopurinol	37	11
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	37	28
Xarelto	Rivaroxaban	36	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	35	12
Oxycodone Hcl	Oxycodone Hcl	34	suppressed
Valsartan	Valsartan	33	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	32	suppressed
Clopidogrel	Clopidogrel Bisulfate	31	11
Oxybutynin Chloride Er	Oxybutynin Chloride	31	suppressed
Prednisone	Prednisone	31	14
Arnuity Ellipta	Fluticasone Furoate	30	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Paroxetine Hcl	Paroxetine Hcl	29	suppressed
Felodipine Er	Felodipine	27	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	27	suppressed
Benazepril Hcl	Benazepril Hcl	24	suppressed
Duloxetine Hcl	Duloxetine Hcl	24	suppressed
Januvia	Sitagliptin Phosphate	24	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	23	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	23	23
Doxycycline Hyclate	Doxycycline Hyclate	23	20
Ipratropium Bromide	Ipratropium Bromide	23	suppressed
Jardiance	Empagliflozin	23	suppressed
Montelukast Sodium	Montelukast Sodium	23	suppressed
Ropinirole Hcl	Ropinirole Hcl	23	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	22	suppressed
Trulicity	Dulaglutide	22	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	22	suppressed
Cephalexin	Cephalexin	21	21
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Spironolactone	Spironolactone	21	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	20	13
Diazepam	Diazepam	20	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	20	suppressed
Diclofenac Sodium	Diclofenac Sodium	19	suppressed
Entresto	Sacubitril/Valsartan	19	suppressed
Hydrocortisone	Hydrocortisone	19	11
Temazepam	Temazepam	19	suppressed
Glipizide	Glipizide	18	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	18	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	17	15
Buspirone Hcl	Buspirone Hcl	17	suppressed
Cefuroxime	Cefuroxime Axetil	17	17
Ciprofloxacin Hcl	Ciprofloxacin Hcl	17	16
Humalog	Insulin Lispro	17	suppressed
Pregabalin	Pregabalin	17	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	15	suppressed
Baclofen	Baclofen	15	suppressed
Bupropion Xl	Bupropion Hcl	15	suppressed
Mounjaro	Tirzepatide	15	suppressed
Azelastine Hcl	Azelastine Hcl	14	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	14	suppressed
Nystatin	Nystatin	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Amiodarone Hcl	Amiodarone Hcl	13	suppressed
Levetiracetam	Levetiracetam	12	suppressed
Methocarbamol	Methocarbamol	12	suppressed
Verapamil Er	Verapamil Hcl	12	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Clonazepam	Clonazepam	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	11	11
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error